TG Therapeutics Inc. (TGTX) is drawing attention after releasing preliminary fourth-quarter and full-year 2025 results, along with 2026 financial guidance and a robust development pipeline update at the 44th Annual J.P. Morgan Healthcare Conference.
The company's BRIUMVI (ublituximab-xiiy) continues to deliver strong commercial performance, positioning TG Therapeutics for sustained growth in the multiple sclerosis (MS) market and beyond.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.